Clinical Trial Update: Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of Opebacan for graft-versus-host disease in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Opebacan

Snippet

Sponsor: XOMA (US) LLC | Conditions: Graft Versus Host Disease | Phase 1, Phase 2 | Status: TERMINATED